22157.jpg
Global Vitrectomy Devices Market (2021 to 2026) - Size, Share & Trends Analysis Report
08 nov. 2021 06h48 HE | Research and Markets
Dublin, Nov. 08, 2021 (GLOBE NEWSWIRE) -- The "Vitrectomy Devices Market Size, Share & Trends Analysis Report By Product, By Application (Diabetic Retinopathy, Retinal Detachment), By End-use...
22157.jpg
Global Retinal Surgery Device Market (2021 to 2027) - Featuring Topcon, Alcon and Carl Zeiss Among Others
25 oct. 2021 04h33 HE | Research and Markets
Dublin, Oct. 25, 2021 (GLOBE NEWSWIRE) -- The "Retinal Surgery Device Market, Global Forecast, Impact of COVID-19, Industry Trends, by Product, Growth, Opportunity Company Analysis" report has been...
22157.jpg
Insights on the Retinal Surgery Devices Global Market to 2026 - Featuring Lumenis, Nidek and Optos Among Others
16 août 2021 08h33 HE | Research and Markets
Dublin, Aug. 16, 2021 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
22157.jpg
Insights on the Vision Care Global Market to 2026 - by Product Type, Distribution Channel and Region
01 juil. 2021 08h18 HE | Research and Markets
Dublin, July 01, 2021 (GLOBE NEWSWIRE) -- The "Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's...
22157.jpg
Global Ophthalmics Partnering Directory 2014-2021: Deals and Contract Documents for Over 550 Ophthalmics Deals
31 mai 2021 04h23 HE | Research and Markets
Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Global Ophthalmics Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The Global...
ONL logo.jpg
ONL Therapeutics Names Connie Chang as Chief Operating Officer
19 janv. 2021 07h00 HE | ONL Therapeutics
ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL logo.jpg
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
22 déc. 2020 07h00 HE | ONL Therapeutics
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
22157.jpg
Outlook on the Retinal Surgery Devices Global Market to 2025 - by Equipment Type, Application, End-use and Region
01 déc. 2020 06h43 HE | Research and Markets
Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204
23 oct. 2019 07h00 HE | ONL Therapeutics
ANN ARBOR, Mich., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Announces First-In-Human Clinical Study with ONL1204
08 oct. 2019 07h00 HE | ONL Therapeutics
Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, Mich., Oct. 08, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical...